STOCK TITAN
  1. Home
  2. Sec-filings
  3. PROK
  4. [Form 4] PROKIDNEY CORP. Insider Trading Activity

Director at PROKIDNEY CORP. (PROK) receives 135,000 stock options as compensation

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

PROKIDNEY CORP. director Jose Ignacio Jimenez Santos received a grant of 135,000 stock options under the company’s non-employee director compensation policy. The options allow him to buy Class A Common Stock at an exercise price of $1.81 per share and expire on May 28, 2036.

The options will vest in full on the earlier of the one-year anniversary of the grant date or the date of the company’s next annual general shareholder meeting. After this award, he holds 135,000 derivative securities related to Class A Common Stock directly.

Positive

  • None.

Negative

  • None.
Insider Jimenez Santos Jose Ignacio
Role null
Type Security Shares Price Value
Grant/Award Director stock option (right to buy) 135,000 $0.00 --
Holdings After Transaction: Director stock option (right to buy) — 135,000 shares (Direct, null)
Footnotes (1)
  1. These options were granted under the Issuer's non-employee director compensation policy. The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.
Options granted 135,000 options Director stock option grant on May 28, 2026
Exercise price $1.81 per share Strike price for Class A Common Stock options
Expiration date May 28, 2036 Option term end for director grant
Holdings after grant 135,000 derivative securities Total director stock options following transaction
Director stock option (right to buy) financial
"Security title is listed as Director stock option (right to buy)."
non-employee director compensation policy financial
"These options were granted under the Issuer's non-employee director compensation policy."
vest in full financial
"The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting."
annual general shareholder meeting financial
"The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Jimenez Santos Jose Ignacio
(Last)(First)(Middle)
C/O PROKIDNEY CORP
2000 FRONTIS PLAZA BLVD, SUITE 250
(Street)
WINSTON SALEM NORTH CAROLINA 27103
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
PROKIDNEY CORP. [ PROK ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Director stock option (right to buy)$1.8105/28/2026A135,000(1) (2)05/28/2036Class A Common Stock135,000$0135,000D
Explanation of Responses:
1. These options were granted under the Issuer's non-employee director compensation policy.
2. The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.
/s/ Todd Girolamo, attorney in fact05/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did PROKIDNEY CORP. (PROK) report for Jose Ignacio Jimenez Santos?

PROKIDNEY CORP. reported that director Jose Ignacio Jimenez Santos received a grant of 135,000 stock options. These options are part of the non-employee director compensation policy and give him rights to acquire Class A Common Stock at a set exercise price.

How many stock options did the PROK director receive and at what exercise price?

The director received 135,000 stock options with an exercise price of $1.81 per share. These options relate to PROKIDNEY CORP.’s Class A Common Stock and represent a compensation award rather than an open-market purchase.

When do the new PROKIDNEY CORP. director stock options vest?

The stock options will vest in full on the earlier of one year from the grant date or the date of PROKIDNEY CORP.’s next annual general shareholder meeting. This single-vesting schedule ties vesting to either time served or the upcoming shareholder meeting.

What is the expiration date of the PROK (PROKIDNEY CORP.) director stock options?

The granted stock options expire on May 28, 2036. After that date, the director can no longer exercise them to purchase Class A Common Stock, so their value depends on exercising during the option term after vesting.

Is the PROK director’s option grant an open-market buy or compensation award?

It is a compensation award, not an open-market purchase. The Form 4 classifies the transaction under code A as a grant or award, and the footnotes state the options were granted under the non-employee director compensation policy.